MedTech Dive January 10, 2024
Stifel analysts expressed support for the decision, predicting it will benefit revenue growth and profitability, and increase focus.
Dive Brief:
- Livanova is closing its circulatory support unit to focus on larger, faster-growing cardiopulmonary and neuromodulation opportunities.
- The advanced circulatory support (ACS) business sells the Lifesparc device, which pumps blood during cardiovascular surgeries, but sales have fallen and then flatlined since peaking in 2021.
- In a note to investors, Stifel analysts said they supported the decision to wind down the unit by the end of 2024, predicting it will benefit revenue growth and profitability and increase focus at the company.
Dive Insight:
Livanova expanded its circulatory support offering by acquiring Tandemlife for $200 million upfront in 2018 and received...
Today's Sponsors
Today's Sponsor
Topics: Medical Devices